IJ
IJF.F ICON Public Limited Company
- Market cap
- EUR 13.4B
- P/E
- 83.2x
- P/B
- 1.65x
- ROE
- 4.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IJF.F undervalued?
Graham numberIJF.F trades 146.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ICON Public Limited Company fundamental analysis
No fundamental analysis for ICON Public Limited Company yet.
ICON Public Limited Company stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of developmen…
Full company profileICON Public Limited Company financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ICON Public Limited Company annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.67B | 1.76B | 2.60B | 2.81B | 2.80B | 5.48B | 7.73B | 8.05B | 8.19B | 8.25B | 8.16B |
| Gross Profit | 705M | 731M | 778M | 832M | 817M | 1.51B | 2.21B | 2.35B | 2.37B | 2.18B | 1.93B |
| Operating Income | 320M | 346M | 386M | 433M | 410M | 608M | 878M | 994M | 1.15B | 1.01B | 776M |
| EBITDA | - | 402M | 444M | 502M | 460M | 694M | 1.40B | 1.47B | 1.50B | 824M | 1.06B |
| Net Income | 262M | 281M | 323M | 374M | 332M | 153M | 506M | 554M | 739M | 229M | 399M |
| EPS | - | 5.20 | 5.98 | 6.97 | 6.30 | 1.88 | 6.20 | 6.72 | 9.15 | 3.00 | 5.33 |
| Balance Sheet | |||||||||||
| Total Assets | 1.83B | 2.15B | 2.35B | 2.91B | 3.44B | 17.4B | 17.3B | 17.0B | 16.9B | 16.3B | 16.2B |
| Total Liabilities | 881M | 956M | 1,000M | 1.29B | 1.59B | 9.32B | 8.69B | 7.75B | 7.35B | 7.08B | 7.12B |
| Shareholders' Equity | 945M | 1.19B | 1.35B | 1.62B | 1.85B | 8.07B | 8.57B | 9.24B | 9.52B | 9.19B | 9.13B |
| Cash & Short-term Investments | 193M | 283M | 396M | 520M | 840M | 752M | 289M | 378M | 539M | 647M | 809M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 259M | 383M | 269M | 413M | 568M | 829M | 563M | 661M | 1.29B | 1.04B | 1.06B |
| Capital Expenditure | 42.6M | 44.7M | 48.4M | 38.9M | 40.9M | 93.8M | 142M | 145M | 168M | 174M | 148M |
| Free Cash Flow | - | 338M | 220M | 362M | 517M | 735M | 474M | 516M | 1.12B | 862M | 910M |
| Ratios | |||||||||||
| ROE | 27.7% | 23.6% | 23.8% | 23.1% | 18.0% | 1.9% | 5.9% | 6.0% | 7.8% | 2.5% | 4.4% |
| ROA | 14.4% | 13.1% | 13.7% | 12.9% | 9.7% | 0.9% | 2.9% | 3.3% | 4.4% | 1.4% | 2.5% |
| Net Profit Margin | 15.7% | 16.0% | 12.4% | 13.3% | 11.9% | 2.8% | 6.5% | 6.9% | 9.0% | 2.8% | 4.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ICON Public Limited Company dividends
ICON Public Limited Company has not paid dividends in the last 9 fiscal years.
Who owns ICON Public Limited Company
- Insiders 0.46%
- Institutions 99.54%
- Public & others 0.00%
- Shares outstanding 74.9M
- Free float 74.9M
ICON Public Limited Company company profile
- Company name
- ICON Public Limited Company
- Ticker
- IJF.F
- ISIN
- IE0005711209
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 40,250
- Fiscal year end
- December
- Address
- South County Business Park, Dublin, Ireland, D18 X5R3
- Phone
- 353 1 291 2000
- Website
- iconplc.com
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
ICON Public Limited Company management
10- Mr. Barry BalfeCEO & Director · born 1979
- Dr. John Climax Ph.D.Founder & Independent Non-Executive Director · born 1953
- Mr. Nigel Clerkin A.C.A.Chief Financial Officer · born 1974
- Mr. Steve EmpolitiChief Commercial Officer
- Lyons EmerChief Accounting Officer
- Mr. Thomas N. O'LearyChief Information Officer
- Mr. Diarmaid CunninghamChief Administrative Officer, General Counsel & Company Secretary · born 1975
- Ms. Niamh MurphyDirector of Corporate Communications
- Mr. David GreenVice President of Marketing
- Mr. Joe CroninChief Human Resources Officer